INVA
Innoviva (INVA)
$
67About Innoviva (INVA)
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
Details
Daily high
$19.83
Daily low
$19.54
Price at open
$19.57
52 Week High
$20.19
52 Week Low
$12.22
Market cap
1.2B
Dividend yield
0.00%
Volume
283,071
Avg. volume
551,942
P/E ratio
11.90
Innoviva News
Details
Daily high
$19.83
Daily low
$19.54
Price at open
$19.57
52 Week High
$20.19
52 Week Low
$12.22
Market cap
1.2B
Dividend yield
0.00%
Volume
283,071
Avg. volume
551,942
P/E ratio
11.90